ReviewInternational journal of molecular sciences2017
Role Played by Signalling Pathways in Overcoming BRAF Inhibitor Resistance in Melanoma.
Review in International journal of molecular sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 86 citations in OpenAlex.
- Synthesis and pharmacokinetic profiling of a novel pyrimidine imidazole based thiosemicarbazone derivative for BRAF inhibition in lung cancer therapy.Discover oncology · 2026Article
- Comparative Proteomic Analysis of the Secretome of Control and BRAF/MEK Inhibitor-Resistant Melanoma Cells.Journal of proteome research · 2026Article
- Investigating the Synergistic Effect of the Cannabis Extract PHEC-66 and Chemotherapeutic Agents on Human Melanoma Cells.International journal of molecular sciences · 2026Article
- Phosphorylation deficient inducible cAMP early repressor (ICER) modulates tumorigenesis and survival in a transgenic zebrafish (Danio rerio) model of melanoma.Biology open · 2025Article
- Antiproliferative Potential of Linagliptin-Rivaroxaban Mixture in Cervical Cancer: Mechanistic Insights into Targeting Mutant MAPK, RAS kinase Signal Protein.Asian Pacific journal of cancer prevention : APJCP · 2025Article
- Current Biomarkers in Non-Small Cell Lung Cancer-The Molecular Pathologist's Perspective.Diagnostics (Basel, Switzerland) · 2025Review
- Skin Cancer: Epidemiology, Screening and Clinical Features of Acral Lentiginous Melanoma (ALM), MelanomaJournal of Cancer · 2025Review
- Navigating the complexity of BRAF mutations in non-small cell lung cancer: current insights and future prospects.Multidisciplinary respiratory medicine · 2024Article
- RAF and MEK Inhibitors in Non-Small Cell Lung Cancer.International journal of molecular sciences · 2024Review
- Cancer-associated Fibroblast-specific Expression of the Matricellular Protein CCN1 Coordinates Neovascularization and Stroma Deposition in Melanoma Metastasis.Cancer research communications · 2024Article
- Evaluating the Mechanism of Cell Death in Melanoma Induced by the Cannabis Extract PHEC-66.Cells · 2024Article
- Article
- Autophagy in BRAF-mutant cutaneous melanoma: recent advances and therapeutic perspective.Cell death discovery · 2023Review
- Role and mechanistic actions of protein kinase inhibitors as an effective drug target for cancer and COVID.Archives of microbiology · 2023Review
- Article
- Therapeutic strategies for BRAF mutation in non-small cell lung cancer: a review.Frontiers in oncology · 2023Review
- Targeted therapies in non-small cell lung cancer: present and future.Faculty reviews · 2023Review
- BRAF Inhibitor Resistance in Melanoma: Mechanisms and Alternative Therapeutic Strategies.Current treatment options in oncology · 2022Review
- BRAF Inhibitors in Non-Small Cell Lung Cancer.Cancers · 2022Review
- Overcoming chemoresistance to b-raf inhibitor in melanoma via targeted inhibition of phosphoenolpyruvate carboxykinase1 using 3-mercaptopropionic acid.Bioengineered · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The discovery of the BRAF
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.